Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017035408) COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/035408 International Application No.: PCT/US2016/048787
Publication Date: 02.03.2017 International Filing Date: 25.08.2016
IPC:
A61K 31/40 (2006.01) ,A61K 31/167 (2006.01) ,A61K 31/395 (2006.01) ,C07D 401/14 (2006.01) ,C07D 403/14 (2006.01) ,C07D 471/04 (2006.01)
[IPC code unknown for A61K 31/40][IPC code unknown for A61K 31/167][IPC code unknown for A61K 31/395][IPC code unknown for C07D 401/14][IPC code unknown for C07D 403/14][IPC code unknown for C07D 471/04]
Applicants:
ACHILLION PHARMACEUTICALS, INC. [US/US]; 300 George Street New Haven, CT 06511, US
Inventors:
WILES, Jason, Allan; US
PHADKE, Avinash, S.; GB
DESHPANDE, Milind; US
AGARWAL, Atul; US
CHEN, Dawei; US
GADHACHANDA, Venkat, Rao; US
HASHIMOTO, Akihiro; US
PAIS, Godwin; US
WANG, Qiuping; US
WANG, Xiangzhu; US
GREENLEE, William; US
Agent:
BELLOWS, Brent, R.; US
Priority Data:
62/210,39126.08.2015US
Title (EN) COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS
(FR) COMPOSÉS POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
Abstract:
(EN) Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.
(FR) L'invention concerne des composés, des méthodes d'utilisation, et des procédés de fabrication d'inhibiteurs du facteur D du complément de formule (I), (I") et (I'''), ou un sel pharmaceutiquement acceptable ou une composition de ceux-ci. Les inhibiteurs décrits dans la description ciblent le facteur D, et inhibent ou régulent la cascade du complément. Les inhibiteurs du facteur D décrits dans la description permettent de réduire l'activation excessive du complément.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)